Sandi MacDonald, Co-founder, President/CEO, International Association for Premenstrual Disorders
Premenstrual disorders such as Premenstrual Dysphoric Disorder (PMDD) remain widely misunderstood, underdiagnosed, and underrepresented in healthcare systems worldwide despite affecting millions of individuals. In this article, the International Association for Premenstrual Disorders explores the critical gaps in access to diagnosis, mental healthcare, peer support, and evidence-based treatment for individuals living with severe premenstrual disorders, and why integrating reproductive mental health into mainstream healthcare is essential for equitable care.
Access to healthcare for women and gender-diverse people is often discussed through the lens of reproductive services, maternal care, or chronic disease management. Yet severe premenstrual disorders and their impact on mental health, daily functioning, and quality of life continue to be overlooked globally.
Premenstrual Dysphoric Disorder (PMDD) is a severe, cyclical neurobiological condition linked to the menstrual cycle. Unlike more commonly recognized premenstrual symptoms, PMDD can cause debilitating emotional, cognitive, and physical symptoms, including depression, anxiety, hopelessness, emotional dysregulation, and suicidality. Symptoms typically emerge during the luteal phase of the menstrual cycle and significantly improve or resolve shortly after menstruation begins.
Although PMDD is formally recognized in both the DSM-5 and ICD-11, it remains significantly underdiagnosed and misunderstood. Many individuals spend years seeking answers while being misdiagnosed with mood disorders, personality disorders, bipolar disorder, or treatment-resistant depression. Others are dismissed entirely, told their symptoms are simply “hormonal,” stress-related, or an expected part of menstruation. The consequences of this gap in understanding can be profound.
Research increasingly demonstrates that individuals living with PMDD experience significantly elevated rates of suicidal ideation, suicide attempts, and suicidality compared to the general population. Yet menstrual-cycle-related mental health symptoms are rarely integrated into standard suicide risk assessments or broader mental healthcare frameworks. Many patients describe repeatedly trying to explain cyclical symptom patterns to healthcare providers who were never trained to recognize or assess reproductive mental health conditions.
One of the most challenging aspects of PMDD is its cyclical nature. Symptoms may become severe for one to two weeks each month and then improve after menstruation begins. This pattern can lead both patients and clinicians to underestimate the seriousness of the condition because symptoms temporarily lessen. However, temporary periods of improvement do not erase the cumulative burden of repeated monthly crises, strained relationships, employment instability, healthcare trauma, and chronic emotional exhaustion.
Access barriers exist at multiple levels. In many regions, there is limited education and training on reproductive mental health conditions within both medical and mental healthcare systems. Specialized care is often inaccessible, particularly in rural, low-resource, or underserved communities. Long wait times for gynecological and psychiatric services can further delay diagnosis and treatment. Even when care is available, patients may struggle to find providers comfortable addressing the intersection of hormonal health and mental health.
Stigma also continues to play a significant role. Discussions surrounding menstruation, mood, and suicidality remain heavily stigmatized in many healthcare systems and societies. As a result, many individuals fear not being believed, worry their symptoms will be minimized, or avoid seeking care altogether due to previous negative healthcare experiences.
At the International Association for Premenstrual Disorders, we have witnessed firsthand the impact that accessible, evidence-based, peer-led support can have for individuals navigating these conditions. Over the past decade, our global community has grown into one of the world’s largest support ecosystems for people affected by PMDD and Premenstrual Exacerbation (PME), offering peer support groups, educational resources, provider directories, advocacy initiatives, and research collaborations.
However, peer support alone cannot address the systemic gaps that persist in healthcare systems. Improving access to care requires broader integration of reproductive mental health into mainstream healthcare systems, medical education, and public health policy. This includes increasing clinician education on PMDD and menstrual-cycle-related mental health conditions, improving early screening and recognition in primary care, gynecology, and mental health settings, and investing more substantially in women’s mental health and reproductive psychiatry research. It also requires trauma-informed, patient-centered approaches to care, stronger collaboration between reproductive health and mental health providers, and more accessible services for underserved and marginalized populations.
Women’s health and gender diverse care cannot be fully addressed without acknowledging the complex relationship between hormones, mental health, and equitable access to care.
For too long, many individuals living with PMDD have navigated severe symptoms in silence, often without validation, appropriate care, or adequate support. As conversations around women’s health continue to evolve globally, reproductive mental health must become part of the broader healthcare equity conversation. Access to healthcare should also mean access to being believed, understood, and appropriately supported.
Suggested References